Solution
What is a differential diagnosis
Differential diagnoses are diseases with similar or almost identical symptoms, which must also be considered by the physician as possible causes of the patient’s complaints in addition to the actual suspected diagnosis.
Do you use 2D or 3D information for search?
While marking a 2D ROI, it is automatically expanded to a 3D ROI. And all the 3D information is taken into account to identify visually-similar patterns.
Is this a web-based solution?
Our solution can be implemented as a web application. However, in order to comply with GDPR and data security regulations, our software is currently hosted within the hospital’s network.
Is your product certified?
contextflow ADVANCE Chest CT v2.0 is CE marked. In addition, our company received its ISO 13485:2016 certification via TüV SüD, meaning we have established a quality management system which meets the requirements of the ISO 13485:2016 standards.
What is malignancy scoring?
A Malignancy Similarity Index (mSI) is a value from 0 to 1 that indicates the degree of similarity between a nodule in question and nodules with known outcomes in a reference set. 0 means no cancer is present, 1 means cancer is present. The mSI score informs clinical decision making which can result in fewer unnecessary procedures and earlier detection of lung cancer.
What are the benefits of malignancy scoring?
Malignancy scoring can help with early detection of lung cancer (up to 1 year sooner). It has also been shown to reduce false positives and negatives. Another goal is to reduce unnecessary, invasive procedures. This is obviously incredibly important to patients with cancer. But even healthy individuals experience stress while waiting for their followups. Malignancy scoring can help focus the healthcare system’s resources on the patients that truly need intervention and provide reassurance to those who don’t.
On which data was mSI trained?
Imaging data from the National Lung Screening Trial (NSLT) was primarily used to develop the mSI tool. Two additional cohorts were gathered and analyzed: an active regional lung screening program, one from the Fred Hutchinson Cancer Research Center (validation cohort) and a cohort consisting of real-world lung nodules from any CT scan in which a nodule was noted from 3 hospitals in Saskatchewan, Canada (used to assess generalizability).
My guideline doesn’t specify use of malignancy scoring. Can I still use it?
Yes! Guidelines are just that…guidelines. Providing the appropriate standard of care means that a doctor must take into account all available information to make an informed decision or recommendation about a patient. Malignancy scoring is another such piece of information.
What do you mean by “downgrading” a nodule?
Let’s say you have a suspicious nodule that requires a biopsy according to the guidelines. However, the malignancy score indicates that this particular nodule is NOT malignant. (Remember, malignancy scoring involves comparing a nodule with tens of thousands of others with known outcomes.) With a low mSI score, this questionable nodule can be downgraded to a lower category in the guidelines, meaning, the biopsy can be avoided, or the followup can be scheduled much later or even removed completely. We understand this is a big change in the way things are normally done, and thus we encourage you to challenge us! Please reach out!
What scientific evidence do you have to support malignancy scoring?
A study on malignancy scoring was published in the Journal of the American College of Radiology in September 2022: Clinical Impact and Generalizability of a Computer-Assisted Diagnostic Tool to Risk-Stratify Lung Nodules with CT.